MTOR and metabolic syndrome: Hypertension and diabetes are affected by the use of calcineurin inhibitors (CNI) and corticosteroids (STR), while dyslipidemia is affected by the use of CNI, STR, and mammalian target of rapamycin (mTOR) inhibitor (Elezaby et al., 2022).